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Aim: This study aimed to assess the cost-effectiveness of starting insulin therapy with
biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes inadequately controlled
on oral glucose-lowering drugs in Saudi Arabia, India, Indonesia, and Algeria.
Methods: The IMS CORE Diabetes Model was used to evaluate economic outcomes associat-
ed with starting BIAsp 30, using baseline characteristics and treatment outcomes from the
A1chieve study. Time horizons of 1 and 30 years were applied, with country-specific costs for
complications, therapies, and background mortality. Incremental cost-effectiveness ratios
(ICERs) are expressed as cost per quality-adjusted life-year (QALY) in local currencies, USD,
and fractions of local GDP per capita (GDPc). Cost-effectiveness was pre-defined using the
World Health Organization definition of <3.0 times GDPc. Comprehensive sensitivity anal-
yses were performed.
Results: In the primary 30-year analyses, starting BIAsp 30 was associated with a projected
increase in life expectancy of >1 year and was highly cost-effective, with ICERs of 0.03
(Saudi Arabia), 0.25 (India), 0.48 (India), 0.47 (Indonesia), and 0.46 (Algeria) GDPc/QALY. The
relative risk of developing selected complications was reduced in all countries. Sensitivity
analyses including cost of self-monitoring, treatment costs, and deterioration of glucose
control with time showed the results to be robust. In a 1-year analysis, ICER per QALY gained
was still cost-effective or highly cost-effective.
Conclusion: Starting BIAsp 30 in people with type 2 diabetes in the A1chieve study was found
to be cost-effective across all country settings at 1- and 30-year time horizons, and usefully
increased predicted life expectancy.
# 2014 Elsevier Ireland Ltd. All rights reserved.
* Corresponding author. Tel.: +44 191 208 7154; fax: +44 191 222 0723.
E-mail address: philip.home@newcastle.ac.uk (P. Home).
Contents available at ScienceDirect
Diabetes Research
and Clinical Practice
journal homepage: www.elsevier.com/locate/diabreshttp://dx.doi.org/10.1016/j.diabres.2014.08.024
0168-8227/# 2014 Elsevier Ireland Ltd. All rights reserved.
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 0 6 ( 2 0 1 4 ) 3 1 9 – 3 2 73201. Introduction
The worldwide prevalence of diabetes is steadily increasing,
and is expected to reach 592 million by 2035 [1]. Global
diabetes-related expenditure, estimated at USD548 billion in
2013, is expected to increase to USD627 billion by 2035 [1]. The
International Diabetes Federation estimates that 80% of
people with diabetes live in low- and middle-income countries
where local health-care systems are often not equipped to deal
with the economic burden of diabetes [2]. Newly developed
countries also have high diabetes prevalence.
In developing and recently developed countries, many
people with diabetes are diagnosed late and may already have
diabetes-related complications, resulting in significant costs
for individuals and families where government-funded
healthcare social security is low or absent. People of working
age are especially affected, with consequences for the
economic potential of the countries [1]. Successful manage-
ment of diabetes includes control of high glucose levels [2,3].
However, many people with type 2 diabetes mellitus (T2DM)
are not achieving the generally recommended levels for good
glycaemic control (HbA1c < 7.0% [<53 mmol/mol]) [2–5].
Analyses of randomised clinical trials (RCTs) [6,7] and data
from non-interventional studies [4,5,8] confirm that beginning
insulin analogues in people taking glucose-lowering drugs
(OGLDs) alone is associated with clinically significant
improvements in glucose control while improving quality of
life. Furthermore, there is evidence to support biphasic insulin
aspart 30 (BIAsp 30) as a cost-effective treatment option in a
number of western and developed countries [9–11].
Evaluation of how health-care funds should be spent to
maximise health benefits requires assessment of the econom-
ic impact of diabetes interventions. Because of the progressive
nature of diabetes and the complexity of the clinical outcomes,
health-economic (HE) data modelling is helpful in estimating
the effects of an intervention on health consequences and
costs. These models can bring together data from a variety of
different sources including RCTs, observational studies, case
registries, public health statistics, and quality-of-life surveys,
simulating disease progression and related costs through time
in a population. In rapidly developing and recently developed
countries where health-care costs are diverse, data from
observational studies can be of use in HE modelling by
reflecting actual outcomes in clinical practice, especially
where there is a paucity of RCT data for these populations
[12–14].
A1chieve was a very large observational study conducted in
countries across Asia, Africa, Eastern Europe, and Latin
America, designed to evaluate the safety and clinical effec-
tiveness of insulin analogues in people with T2DM in clinical
practice [4]. It thus provides an opportunity to explore how the
insulin analogues performed in diverse, heterogeneous
populations and to conduct cost-effectiveness analyses in
non-western populations. In turn, this may help the evolution
of diabetes guidelines and enable the optimal allocation of
scarce health-care resources. Furthermore, the prospective
use of the globally validated EQ-5D instrument provides a
unique opportunity to base the health-related quality of life
(HRQoL) data used as input in the HE model on answers fromthe same population as the clinical outcomes are observed.
The aim of the present analysis is to assess the long- and
short-term cost-effectiveness of starting BIAsp 30 in people
with T2DM poorly controlled on OGLDs applying the specific
EQ-5D and clinical outcome data collected during the A1chieve
study.
2. Participants and methods
2.1. A1chieve data collection
A1chieve was a 24-week, international, non-interventional,
observational study in insulin-naı¨ve and insulin-experi-
enced people with T2DM from 28 countries starting treat-
ment with BIAsp 30, insulin detemir, or insulin aspart (all
Novo Nordisk, Copenhagen, Denmark)  OGLDs in routine
clinical practice. Details of the study design and methods
and global primary data have been published elsewhere
[4,15]. In summary, data were collected on clinical effective-
ness and adverse events at routine clinical visits (baseline, 12
and 24weeks). Participants were asked to complete the EQ-
5D questionnaire, used for self-assessment of HRQoL, at
baseline and week 24 [15].
2.2. Simulation cohort
The cost-effectiveness analysis used clinical data from the
A1chieve study for the measurement of health outcomes. Data
were included for people being treated for diabetes with
OGLDs alone at pre-study and starting BIAsp 30 at baseline, in
most cases keeping at least part of the OGLD treatment. To
secure reliable estimates and for the analysis to be represen-
tative for the average population, only countries where more
than 100 insulin-naı¨ve people started BIAsp 30 were included.
An HbA1c result at both baseline and end of study was also
required. These criteria result in study populations from Saudi
Arabia (n = 901), India (n = 7546), and Indonesia (n = 153), and
three North African countries grouped together (Algeria,
Tunisia, and Morocco; n = 279), analysed using economic data
from Algeria. The prevalence of diabetes has risen dramati-
cally in these neighbouring countries in recent years and they
have experienced similar rapid economic development and
changes in lifestyle that endorse their assignment as a single
population, defined specifically by treatment choice, for this
analysis [16]. Baseline characteristics of the defined popula-
tions, and changes in blood-glucose control, body mass index,
plasma lipids, systolic blood pressure, hypoglycaemia, and EQ-
5D-based HRQoL are shown in Table 1.
The clinical and economic costs of starting BIAsp30 (with or
without changes to OGLDs) in each country were projected over
a 30-year time horizon for the base-case using the IMS CORE
Diabetes Model (version 8.5; Basel, Switzerland) [17,18]. Baseline
and clinical data from the A1chieve cohorts were used together
with economic data including annual diabetes management
costs (medications and surveillance tests) and relevant co-
morbid medical conditions taken from the published literature
[19–22]. The costs of BIAsp30 and OGLDs were sourced from
local Novo Nordisk affiliates. Both costs and effects were
discounted at an annual rate of 3.0% according to World Health
Table 1 – Baseline characteristics and change in clinical outcomes after 24 weeks from the A1chieve study in people
starting BIAsp 30 + OGLDs inadequately controlled on OGLDs alone.
Saudi Arabia India Indonesia Algeria
n 901 7546 153 279
Sex, M/F (%) 66.2/33.8 63.0/37.0 62.1/37.9 49.1/50.9
Age (years) 51.0 (8.4) 50.4 (9.0) 51.2 (9.6) 57.0 (10.5)
Diabetes duration (years) 9.7 (5.5) 5.7 (3.7) 5.9 (4.7) 8.9 (6.4)
BMI (kg/m2/change) 31.2 (5.0)/0.3 26.0 (3.2)/0.1 23.5 (3.5)/1.1 26.2 (4.1)/0.8
HbA1c (%/change) 10.1 (1.7)/2.70* 9.2 (1.3)/1.9* 10.1 (1.6)/2.90* 10.1 (2.0)/2.60*
HbA1c mmol/mol/mean change 86.9 (18.6)/29.5* 77.0 (14.2)/20.8* 86.9 (17.5)/31.7* 86.9 (21.9)/26.2*
BIAsp dose (U/day) 24 weeks/mean
change from baseline
58.8 (18.9)/12.2 24.8 (7.7)/0.6 37.5 (10.3)/12.1 45.7 (14.9)/10.2
EQ-5D/change 0.566/0.243y 0.485/0.312* 0.807/0.154* 0.673/0.152*
Systolic blood pressure (mmHg/change) 133.8 (15.3)/6.2* 141.4 (26.7)/10.0* 128.6 (11.6)/5.4* 134.0 (16.2)/2.7*
Baseline complications, n (%)
Cardiovascular 317 (27.3) 1640 (23.4) 19 (12.4) 41 (14.7)
Renal 574 (49.4) 1398 (20.0) 8 (5.2) 67 (24.0)
Eye 446 (38.4) 4474 (64.0) 14 (9.2) 80 (28.7)
Foot ulcer 87 (7.5) 336 (4.8) 6 (3.9) 9 (3.2)
Neuropathy 695 (59.9) 1326 (19.0) 35 (22.9) 86 (30.8)
Lipids (mmol/L)/change
Total cholesterol 5.3 (1.2)/0.8* 4.5 (1.1)/0.0* 5.7 (1.1)/0.8* 5.1 (1.3)/0.4*
LDL cholesterol 3.2 (0.9)/0.6* 3.2 (0.9)/0.3* 3.4 (1.1)/0.3 3.2 (1.3)/0.4
HDL cholesterol 1.1 (0.2)/0.1* 1.0 (0.2)/0.0* 1.4 (0.5)/0.0 1.1 (0.4)/0.1
Triglycerides 2.2 (1.0)/0.4* 2.0 (0.7)/0.3* 1.8 (1.2)/0.5* 1.7 (0.9)/0.2
Hypoglycaemia (Events per 100
patient-years)/change
Daytime
Major 0.04/0.04 0.02/0.02 0.00/0 0.93/0.84
Minor 0.75/+0.71 0.54/0.40 0.85/0.85 3.49/+1.17
Nocturnal
Major 0.00/0 0.01/0.01 0.00/0 1.21/1.21
Minor 0.20/+0.19 0.23/0.22 0.34/0.34 2.52/0.47
Mean (SD or %), * p < 0.001.
BIAsp 30, biphasic insulin aspart 30; BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; OGLD, oral glucose-
lowering drug.
y No country-specific data available. Average is calculated from EQ-5D data of other countries from A1chieve.
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for each country were taken from WHO data tables.
A short-term analysis (for the first year after starting BIAsp
30) was conducted using the incremental cost of treatment
and the incremental effect on EQ-5D only.
2.3. CORE diabetes model
The CORE Diabetes Model is an analysis tool for both type 1
and type 2 diabetes. Independent and non-product-specific, it
takes into account costs for diabetes-related therapy (acquisi-
tion costs of the insulin) and management (current clinical
management activity), and complication costs (including
screening and treatment strategies for micro- and macro-
vascular complications, and treatment practices for end-stage
complications). The interactive computer simulation of
disease progression is based on a series of interdependent
Markov submodels that simulate the progression of diabetes-
associated complications. A full description of the models has
been previously published [17,18]. Each of the models applies
time, health state, duration of health state, and diabetes type-
dependent probabilities predominately derived from the
published UKPDS, DCCT, and Framingham studies. The
reliability of the model has been validated against clinical
trial reports [17]. Baseline, clinical, and economic data can beentered by the user, allowing projection of country-specific
short- and long-term outcomes and costs. A1chieve study-
specific change in EQ-5D HRQoL scores from the participating
countries [8] replaced the default CORE values in the current
analysis.
2.4. Statistics
Non-parametric bootstrapping was used in each simulation
(1000 people and 1000 bootstraps per country) to construct
confidence intervals around the data [23]. The incremental
cost-effectiveness ratio (ICER) per quality-adjusted life-year
(QALY) was calculated in local currency, USD, and as a fraction
of the gross domestic product (GDP) per capita for each
country. ICERs reveal the cost per unit of benefit from
switching from one treatment to another and GDP data were
taken from the World Bank report for 2011 [24]. Cost-
effectiveness was pre-defined according to the WHO CHOos-
ing Interventions that are Cost-Effective (CHOICE) programme
threshold based on GDP per capita [25]. Categorisation by this
system defines a health technology to be cost-effective if
incremental cost per incremental QALY gained falls between
1.0 and 3.0 times GDP per capita, highly cost-effective if <1.0
GDP per capita, and dominant (i.e., cost-saving) if costs per
QALY gained are <0.0.
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how robust the findings of the base-case analysis would be if
the assumptions made in the model were varied. A sensitivity
analysis on the time horizon was performed by extending the
time horizon to 50years, ensuring everyone was dead at the
end of the study period. The impact of cost changes was
examined assuming two self-measured blood glucose (SMBG)
strips per day versus zero strips in the base-case; four
additional visits to the healthcare practitioner in the first
year following starting insulin (first visit to a specialist, others
in primary care); two general practitioner visits every year
after starting insulin; comparator arm starting BIAsp 30 after
5 years rather than staying on OGLDs indefinitely. The impact
of HbA1c changes was assessed by assuming no change in
HbA1c over time (+0.15%-unit increase in HbA1c per year used
in base-case scenario after first year), the median rather than
mean change in HbA1c, and the HbA1c treatment effect in the
quarter of the population with the smallest change. A further
sensitivity analysis used average A1chieve EQ-5D data for
BIAsp 30 rather than country-specific data. For the 1-year
short-term analysis, sensitivity analyses were conducted by
adding the cost of monitoring strips and for four general
practitioner visits, respectively.
An analysis was also conducted to project the maximum
putative cost of treatment that would result in an ICER of three
times GDP per capita, i.e., the limit of cost-effectiveness, to
assess the room for additional costs not taken into account in
the base-case analyses.
3. Results
3.1. Life expectancy, diabetes-related complications, costs,
and cost-effectiveness
The significant improvements in surrogate clinical outcomes
following change in therapy to BIAsp 30  OGLDs in people
with T2DM (Table 1) were associated with projected improve-
ments in life expectancy of 1.9 years in Saudi Arabia, 1.3 years
in India, 1.8 years in Indonesia, and 1.5 years in Algeria.Table 2 – Incidence (percentage of people) and estimated time
starting BIAsp 30+ OGLDs in insulin-naı¨ve people with T2DM tr
Algeria.
Saudi Arabia Indi
BIAsp 30 OGLD BIAsp 30 
Severe vision loss
Incidence (% people) 7.88 12.21 6.88 
Time to event (years) 13.03 10.91 15.06 
End-stage renal disease
Incidence (% people) 5.57 17.23 3.37 
Time to event (years) 13.51 11.39 15.50 
Myocardial infarction
Incidence (% people) 31.59 39.31 31.89 
Time to event (years) 11.72 9.67 13.56 
Ulcer
Incidence (% people) 40.66 41.49 15.36 
Time to event (years) 10.15 8.57 14.28 
BIAsp 30, biphasic insulin aspart 30; OGLD, oral glucose-lowering drug; TProjected reductions in 30-year incidence of diabetes-
related complications compared with OGLD treatment alone
are shown in Table 2. Expressed as relative risk, the risk of a
myocardial infarction event was reduced by 20% (Saudi
Arabia), 19% (India), 32% (Indonesia), and 22% (Algeria). The
risk of blindness was reduced by 35% in Saudi Arabia and
India, 47% in Indonesia, and 33% in Algeria. The risk of dialysis
was projected to fall by between 64% (India) and 78%
(Indonesia), and the risk of foot ulceration by between 2%
(Saudi Arabia) and 23% (Indonesia). The time free of any
complication in people with T2DM was greater with
BIAsp 30  OGLDs compared with OGLD treatment alone;
the difference between treatments ranged between a gain of
2.0 years in Indonesia and 0.18 years in Saudi Arabia. Similar
trends in delayed onset were observed for other complications
(Table 2). The estimated QALY gains were 2.77 for Saudi
Arabia, 4.57 for India, 2.73 for Indonesia, and 2.65 for Algeria.
The projected differences in glucose-lowering treatment
costs, management costs, complication-related costs, and
overall costs after switching therapy from OGLD only to
BIAsp 30  OGLDs over a 30-year time horizon are shown in
Table 3. While therapy costs were higher with insulin in all
countries, and management costs similar, complication-
related costs were lower. Accordingly, change in overall
health-care expenditure ranged from 42% higher in Algeria
to 4% lower in Saudi Arabia; India (+30%) and Indonesia (+20%)
were intermediate. Expressed in US dollar terms, the
discounted average extra cost per person ranged from cost-
saving in Saudi Arabia to USD165 per year in Algeria (Table 3).
The long- and short-term cost-effectiveness of starting
BIAsp 30 +/ OGLDs in insulin-naı¨ve people with T2DM from
Saudi Arabia, India, Indonesia, and Algeria is shown in Table 4.
Base-case analysis (30 years) showed India, Indonesia, and
Algeria to have an ICER per QALY gained of <1.0 GDP per capita
(0.25, 0.47, and 0.46, respectively) compared to OGLD therapy,
meeting the definition of highly cost-effective. As BIAsp 30
delivered both discounted cost savings and marked improve-
ments in health outcomes in Saudi Arabia, the insulin therapy
was cost-saving over OGLDs alone. In the short-term 1-year
analysis, ICER per QALY gained after starting BIAsp 30 therapy alive and free of complications (years) over 30 years after
eated with OGLDs from Saudi Arabia, India, Indonesia, and
a Indonesia Algeria
OGLD BIAsp 30 OGLD BIAsp 30 OGLD
10.57 6.30 11.97 9.21 13.71
13.48 16.63 14.44 14.61 12.37
9.43 2.69 12.37 4.73 13.67
14.05 17.11 15.14 14.97 13.30
39.24 19.46 28.65 27.03 34.51
12.01 16.26 14.15 13.61 11.85
19.32 16.96 21.97 18.06 21.15
12.79 15.70 13.68 13.67 12.09
2DM, type 2 diabetes mellitus.
Table 3 – Cost simulated over 30 years with BIAsp 30 + OGLDs compared with the cost of OGLD therapy.
Saudi Arabia India Indonesia Algeria
BIAsp 30 OGLD BIAsp 30 OGLD BIAsp 30 OGLD BIAsp 30 OGLD
Total costs
Local
currency
189,473 SAR 196,760 SAR 411,046 INR 317,362 INR 290,767,442 IDR 242,748,340 IDR 1402,600 DZD 990,010 DZD
USD 49,263 51,158 7399 5713 29,077 24,275 16,831 11,880
Treatment
costs
Local
currency
37,821 SAR 18,648 SAR 215,335 INR 76,114 INR 119,409,114 IDR 34,444,198 IDR 682,407 DZD 213,950 DZD
USD 9833 4848 3876 1370 11,941 3444 8189 2567
Management
costs
Local
currency
39,559 SAR 35,996 SAR 55,114 INR 53,653 INR 49,563,613 IDR 47,945,153 IDR 428,538 DZD 401,841 DZD
USD 10,285 9359 992 966 4956 4795 5142 4822
Complication
costs
Local
currency
112,093 SAR 142,116 SAR 140,598 INR 187,594 INR 121,795,715 IDR 160,358,989 IDR 291,655 DZD 374,220 DZD
USD 29,144 36,950 2531 3377 12,179 16,036 3500 4491
Currency conversions as of September 2013 (1 SAR = 0.26 USD, 1 IDR = 0.0001 USD, 1 INR = 0.018 USD, 1 DZD = 0.012 USD).
North Africa combined Algeria, Morocco and Tunisia, expressed in Algerian currency.
BIAsp 30, biphasic insulin aspart 30; OGLD, oral glucose-lowering drug.
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of GDP per capita), India (0.43), and Algeria (0.73), while being
cost-effective in Indonesia (1.20 of GDP per capita) (Table 4).
3.2. Sensitivity analyses
The series of sensitivity analyses revealed that there was little or
no impact on ICERs. This was true for extending the time horizon
to 50 years, if no deterioration with time in HbA1c was factored
into the model, and if the median HbA1c treatment effect was
used in place of the mean value (Fig. 1). Similarly, there was little
effect of two additional primary care visits in every year following
start of BIAsp 30 or if the average global EQ-5D value replaced the
country-specific data (Fig. 1). If BIAsp 30 was begun after 5 years in
the OGLD group, but the model still ran for 30 years, the ICERs
were projected to change only marginally in Saudi Arabia and
were lower than for the base-case analysis in India, Indonesia,Table 4 – Long-term (30-year time horizon) and short-term (1-
30 + OGLDs in insulin-naı¨ve people with T2DM from Saudi Ar
Saudi Arabia 
30-year ICER (cost per QALY gained)
(base-case)
Local currency 2063 SAR 
USD 550 
GDP fraction 0.03 
1-year ICER (cost per QALY gained)
Local currency 6340 SAR 
USD 1690 
GDP fraction 0.08 
Currency conversions as of September 2013 (1 SAR = 0.26 USD, 1 IDR 
combined Algeria, Morocco and Tunisia, expressed in Algerian currency
BIAsp 30, biphasic insulin aspart 30; ICER, incremental cost-effectiveness 
year; T2DM, type 2 diabetes mellitus.and Algeria (Fig. 1). The results were more sensitive to using the
lowest quarter data for the HbA1c treatment effect and to the
inclusion of treatment costs with either additional SMBG strip use
or including four additional clinic visits in the first year after the
change in therapy. Nevertheless, the predicted outcomes (ICER)
were still well within the cost-effective range (ICER < 3.0 ratio to
GDP per capita).
The increase in total current costs that would still deliver
an ICER of 3.0 GDP/QALY (i.e., which would be on the cost-
effectiveness limit) was estimated to be 90% for Indonesia,
161% for Algeria, 252% for India, and 435% for Saudi Arabia.
4. Discussion
This analysis has used country-specific data for healthcare
costs, combined with country-specific short-term healthyear time horizon) cost-effectiveness of starting BIAsp
abia, India, Indonesia, and Algeria.
India Indonesia Algeria
20,516 INR 15,710,332 IDR 155,659 DZD
370 1632 1955
0.25 0.47 0.46
35,182 INR 40,487,477 IDR 246,422 DZD
635 4206 3095
0.43 1.20 0.73
= 0.0001 USD, 1 INR = 0.018 USD, 1 DZD = 0.012 USD); North Africa
.
ratio; OGLD, oral glucose-lowering drug; QALY, quality- adjusted life-
Fig. 1 – Sensitivity analysis of BIAsp 30 W OGLDs in people with T2DM inadequately controlled on OGLDs from Saudi Arabia,
India, Indonesia, and Algeria. Results presented as a fraction of GDP per capita per QALY gained. BIAsp 30, biphasic insulin
aspart 30; GDP, gross domestic product; GP, general practitioner; OGLD, oral glucose-lowering drug; QALY, quality-adjusted
life-year; SMBG, self-measured blood glucose; T2DM, type 2 diabetes mellitus; ICER, incremental cost-effectiveness ratio.
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long-term (base-case 30 years) costs and health outcomes
associated with starting BIAsp 30 with or without OGLDs
according to local practice in people with T2DM in routine
diabetes care. Although the total population studied inA1chieve was large, individual country populations started
on this insulin restricted the analysis to four countries (after
combining data for Algeria, Morocco, and Tunisia), with large
numbers of people from India and Saudi Arabia, and smaller
but useful numbers from Algeria and Indonesia. These four
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development, and culture, but nevertheless, when adjusted to
GDP using the WHO CHOICES criteria, starting insulin therapy
with BIAsp 30 was highly cost-effective by the base-case in all
of them (Table 4). The positive clinical outcomes from these
participants in the A1chieve study (Table 1.) are likely to have
contributed to this finding, as improved glycaemic control and
HRQoL have been associated with reduced health-care costs in
adults with diabetes [26,27].
Due to the chronic nature of diabetes and the severity of
associated complications, diabetes is a very costly disease.
These costs are not only financial, affecting, directly or
indirectly, the individual and their families, in addition to
social care. Studies in India indicate that the economic burden
of diabetes care on families is rising rapidly, with 85–95% of all
healthcare costs being borne by individuals and their families
from household income [28,29]. Taking into consideration that
people diagnosed with diabetes can have significantly higher
healthcare requirements and expenditures than in the
absence of diabetes, the growing prevalence of diabetes will
pose tremendous future challenges for low to middle-income
countries [30,31]. In this context, an intervention that can
deliver increased life expectancy of >1 year with reduced
incidence of diabetes-related complications and delayed onset
of these would appear attractive.
As might be expected, costs of treatment, management, and
complications were much higher in Saudi Arabia than other
counties (and lowest in India) due to the economic circum-
stances of the country. However, the modelled extra treatment
costs of starting BIAsp 30 are largely balanced out by the lower
overall complication rates and, therefore, the lower estimated
costs of complication management, including specific treat-
ment costs and management costs related to those complica-
tions (Table 3). This offset effect is not complete, except in Saudi
Arabia, largely because the complication costs per se are much
lower, expressed in GDP per capita. Nevertheless, the ICERs are
still all under a sixth of the WHO threshold for cost-effective-
ness in the base-case. While the analysis showed cost savings in
Saudi Arabia, this was not driven by differences in modelled
outcomes or a larger reduction in outcomes compared to the
other countries. Within the limits of the assumptions made,
the numbers of people affected by adverse health events
were broadly similar between the four countries, as were the
improvements expected in clinical outcomes often associated
with starting insulin (Table 2).
The Indonesian and Algerian data are intermediate com-
pared with Saudi Arabia and India, Indonesian and Algerian
estimates for diabetes as a proportion of total health-care
expenditure being 7% and 11% of total in 2010 [32]. Both of these
A1chieve sub-populations reported relatively poor glycaemic
control at baseline (mean HbA1c 10.1%; 86.9 [18.6] mmol/mol)
and thus had an opportunity for larger improvements at
24 weeks (2.9%-units in Indonesia; 2.6%-units in Algeria). As
HbA1c is a major driver of reduced complications in diabetes,
and thus in the CORE Diabetes Model, the proportionately
high reductions in the cost of complications are estimated
(Table 2 and 3), and the ICER associated with the intervention is
highly cost-effective in GDP terms here too.
The results of the CORE modelling do not support the view,
mostly from developed nations, that the costs of diabetes aredriven overall by the costs of managing its complications [33].
Rather, in this analysis, they are close to being in balance. This
disparity is perhaps explained by our population having T2DM
and being rather older, such that death from other co-
morbidities restricts the opportunity to suffer some vascular
complications and to incur their costs over many years. The
problem remains that, for health authorities or individuals
alike, the increased cost of effective diabetes management
does have to be accepted to gain savings or potential health
benefits in the longer term. However, in this analysis, the
short-term model, for the first year after starting BIAsp 30,
based only on the incremental cost of treatment and the
incremental effect on EQ-5D, indicated that an early benefit
could be possible.
A number of studies have examined long-term clinical and
economic outcomes after starting BIAsp 30 in western nations
and in South Korea [9,10,34–36], finding it to be cost-effective.
Palmer and colleagues, using data from the PRESENT study,
examined the cost-effectiveness of converting from biphasic
human insulin to BIAsp 30 in China. They found that the
increased costs are largely offset by reduction in complication
costs, but with improved outcomes giving a high level of cost-
effectiveness [37]. Also of partial relevance to the current study
is a cost-effectiveness analysis of conversion from biphasic
human insulin to BIAsp 30 in Saudi Arabia, again based on data
from the PRESENT study, which found cost savings with
improved outcomes (dominance) when using the CORE
Diabetes Model [28]. As well as extending this last analysis
to the more typical situation of people starting insulin, in the
current study the global range of HE analysis is much extended
by the modelling for other countries.
The strengths and weaknesses of the underlying A1chieve
observational study data have been discussed elsewhere,
limitations including the relatively short observation period,
the likelihood of lifestyle change accompanying the starting of
insulin therapy, and the possibility of regression to the mean
in core surrogate outcomes such as HbA1c [4,15]. Being an
observational study, there is no control group, so we can only
make HE comparisons against baseline therapy. While the
intervention was still cost-effective using only HRQoL data
over 1 year, it could be argued that our other sensitivity
analysis, where all participants were converted to insulin at 5
years, modelled an unacceptable delay in starting insulin. The
cost-effectiveness evaluations used here carry other uncer-
tainties, such as the relevance of the underlying equations
based on studies like UKPDS and the Framingham Heart Study
to the populations studied in A1chieve. However the IMS CORE
Diabetes Model has been validated against a number of
epidemiological and clinical studies, and country-specific
epidemiological data. Furthermore, we have performed a
number of sensitivity analyses, including testing fundamental
assumptions such as continued deterioration with time, using
a conservative measure of HbA1c change, and modelling
different time horizons (Fig. 1). None of these markedly affect
the cost-effectiveness. The finding that the 1-year estimate,
using only first-year costs and improvement in health utility
based on the EQ-5D data, was also cost-effective perhaps
indicates that the improvement in HRQoL makes a large
contribution to the model outputs, thus reducing the impact of
longer-term gains and costs. The sensitivity analysis that
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 0 6 ( 2 0 1 4 ) 3 1 9 – 3 2 7326otherwise most changed the ICERs was increase in use of
SMBG strips, although, even here, all ICERs remained below
the cost-ineffectiveness threshold.
Some uncertainties remain around health-care costs.
While some were obtained from published and official sources
for each country, local diabetes specialists were requested to
provide values when no published data were available.
Although consensus of up to three specialists was used to
attempt to reduce error, some bias is inevitable. In addition,
we are not able to account for changes in adherence to
injection therapy in the longer term, nor rising insulin dose
(and thus insulin costs) with time. For this reason, in the
sensitivity analyses we explored the increase in potential
overall costs that would still allow the intervention to be cost-
effective at an ICER of 3.0 times GDP per capita, finding
markedly higher incremental costs would be needed, leaving
room for adding to the treatment costs over time.
To conclude, with the worldwide prevalence of diabetes
steadily increasing and placing ever greater demand on
national healthcare expenditure, policymakers need informa-
tion not only on the safety and effectiveness of an intervention
but also on whether it provides good value for money in relation
to the cost of treatment. Using clinical data from the A1chieve
observational study, analysed using the IMS CORE Diabetes
Model, our findings indicate that starting insulin therapy with
BIAsp 30 in people with poorly controlled T2DM on OGLDs alone
is considered to be a highly cost-effective intervention in India,
Indonesia, Algeria, and Saudi Arabia. The findings are robust,
being reproduced across a number of sensitivity analyses.
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